The myocardial contraction fraction is superior to ejection fraction in predicting survival in patients with AL cardiac amyloidosis

References

• Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, Salvi F, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 2009;120:1203–12
   PubMed Web of Science ®Google Scholar
• Ruberg FL, Maurer MS, Judge DP, Zeldenrust S, Skinner M, Kim AY, Falk RH, et al. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J 2012;164:222–8
   PubMed Web of Science ®Google Scholar
• Liao R, Jain M, Teller P, Connors LH, Ngoy S, Skinner M, Falk RH, et al. Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation 2001;104:1594–7
   PubMed Web of Science ®Google Scholar
• King DL, El-Khoury Coffin L, Maurer MS. Myocardial contraction fraction: a volumetric index of myocardial shortening by freehand three-dimensional echocardiography. J Am Coll Cardiol 2002;40:325–9
   PubMedGoogle Scholar
• Lindqvist P, Olofsson BO, Backman C, Suhr O, Waldenstrom A. Pulsed tissue Doppler and strain imaging discloses early signs of infiltrative cardiac disease: a study on patients with familial amyloidotic polyneuropathy. Eur J Echocardiog 2006;7:22–30
   PubMed Web of Science ®Google Scholar
• Koyama J, Falk RH. Prognostic significance of strain Doppler imaging in light-chain amyloidosis. JACC Cardiovasc Imag 2010;3:333–42
   PubMed Web of Science ®Google Scholar
• Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, Solomon SD, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 2010;23:685–713; quiz 86–8
   PubMed Web of Science ®Google Scholar
• Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989;2:358–67
   PubMed Web of Science ®Google Scholar
• de Simone G, Devereux RB, Ganau A, Hahn RT, Saba PS, Mureddu GF, Roman MJ, et al. Estimation of left ventricular chamber and stroke volume by limited M-mode echocardiography and validation by two-dimensional and Doppler echocardiography. Am J Cardiol 1996;78:801–7
   PubMed Web of Science ®Google Scholar
• Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986;57:450–8
   PubMed Web of Science ®Google Scholar
• Rapezzi C, Riva L, Quarta CC, Perugini E, Salvi F, Longhi S, Ciliberti P, et al. Gender-related risk of myocardial involvement in systemic amyloidosis. Amyloid 2008;15:40–8
   PubMed Web of Science ®Google Scholar
• Connors LH, Prokaeva T, Lim A, Theberge R, Falk RH, Doros G, Berg A, et al. Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. Am Heart J 2009;158:607–14
   PubMed Web of Science ®Google Scholar
• Kristen AV, Perz JB, Schonland SO, Hegenbart U, Schnabel PA, Kristen JH, Goldschmidt H, et al. Non-invasive predictors of survival in cardiac amyloidosis. Eur J Heart Fail 2007;9:617–24
   PubMed Web of Science ®Google Scholar
• Austin BA, Duffy B, Tan C, Rodriguez ER, Starling RC, Desai MY. Comparison of functional status, electrocardiographic, and echocardiographic parameters to mortality in endomyocardial-biopsy proven cardiac amyloidosis. Am J Cardiol 2009;103:1429–33
   PubMed Web of Science ®Google Scholar
• Migrino RQ, Harmann L, Woods T, Bright M, Truran S, Hari P. Intraventricular dyssynchrony in light chain amyloidosis: a new mechanism of systolic dysfunction assessed by 3-dimensional echocardiography. Cardiovasc Ultrasound 2008;6:40
   PubMed Web of Science ®Google Scholar
• Bhuiyan T, Helmke S, Patel AR, Ruberg FL, Packman J, Cheung K, Grogan D, et al. Pressure-volume relationships in patients with transthyretin (ATTR) cardiac amyloidosis secondary to V122I mutations and wild-type transthyretin: Transthyretin Cardiac Amyloid Study (TRACS). Circulation Heart Fail 2011;4:121–8
   PubMedGoogle Scholar
• Bellavia D, Pellikka PA, Al-Zahrani GB, Abraham TP, Dispenzieri A, Miyazaki C, Lacy M, et al. Independent predictors of survival in primary systemic (Al) amyloidosis, including cardiac biomarkers and left ventricular strain imaging: an observational cohort study. J Am Soc Echocard 2010;23:643–52
   PubMed Web of Science ®Google Scholar
• Buss SJ, Emami M, Mereles D, Korosoglou G, Kristen AV, Voss A, Schellberg D, et al. Longitudinal left ventricular function for prediction of survival in systemic light-chain amyloidosis: incremental value compared with clinical and biochemical markers. J Am Coll Cardiol 2012;60:1067–76
   PubMed Web of Science ®Google Scholar
• Perlini S, Salinaro F, Musca F, Mussinelli R, Boldrini M, Raimondi A, Milani P, et al. Prognostic value of depressed midwall systolic function in cardiac light-chain amyloidosis. J Hypertens 2014;32:1121–31
   PubMed Web of Science ®Google Scholar
• King DL, Coffin Lel K, Maurer MS. Noncompressibility of myocardium during systole with freehand three-dimensional echocardiography. J Am Soc Echocardiograph 2002;15:1503–6
   PubMedGoogle Scholar
• Chuang ML, Gona P, Salton CJ, Yeon SB, Kissinger KV, Blease SJ, Levy D, et al. Usefulness of the left ventricular myocardial contraction fraction in healthy men and women to predict cardiovascular morbidity and mortality. Am J Cardiol 2012;109:1454–8
   PubMed Web of Science ®Google Scholar
• Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation 2005;112:2047–60
   PubMed Web of Science ®Google Scholar
• Mishra S, Guan J, Plovie E, Seldin DC, Connors LH, Merlini G, Falk RH, et al. Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish. Am J Physiol 2013;305:H95–103
   PubMed Web of Science ®Google Scholar
• Shi J, Guan J, Jiang B, Brenner DA, Del Monte F, Ward JE, Connors LH, et al. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proc Natal Acad Sci USA 2010;107:4188–93
   PubMed Web of Science ®Google Scholar
• Karamitsos TD, Piechnik SK, Banypersad SM, Fontana M, Ntusi NB, Ferreira VM, Whelan CJ, et al. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imag 2013;6:488–97
   PubMed Web of Science ®Google Scholar
• Sun JP, Stewart WJ, Yang XS, Donnell RO, Leon AR, Felner JM, Thomas JD, et al. Differentiation of hypertrophic cardiomyopathy and cardiac amyloidosis from other causes of ventricular wall thickening by two-dimensional strain imaging echocardiography. Am J Cardiol 2009;103:411–15
   PubMed Web of Science ®Google Scholar
• Ford WR, Menon V, Bhambhani A, Liyanage R, Khan MI, Jugdutt BI. Changes in myocardial density during postinfarction healing: effect on estimation of in vivo left ventricular mass by echocardiographic imaging. Canad J Physiol Pharmacol 1997;75:1075–82
   PubMedGoogle Scholar